Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Hoffmann, KM; Moser, A; Lohse, P; Winkler, A; Binder, B; Sovinz, P; Lackner, H; Schwinger, W; Benesch, M; Urban, C.
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.
Blood. 2008; 112(5): 1655-1657. Doi: 10.1182/blood-2008-03-147785 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Führende Autor*innen der Med Uni Graz
Hoffmann Karl Martin
Co-Autor*innen der Med Uni Graz
Benesch Martin
Binder Barbara
Lackner Herwig
Nebl Andrea Maria
Ritter-Sovinz Petra
Schwinger Wolfgang
Urban Ernst-Christian
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Cutaneous mastocytosis (CM) in children is a usually benign skin disorder caused by mast cell proliferation. Progressive disease leading to systemic involvement and fatal outcomes has been described. C-kit receptor mutations have been identified as causative for CM, some of which potentially respond to imatinib treatment as described for patients with systemic mastocytosis. We report successful therapy of progressive CM with imatinib in a 23-month-old boy. KIT gene analysis revealed not only a somatic deletion of codon 419 in exon 8 (c.1255_1257delGAC) which responds to imatinib therapy, but also a novel germ line p. Ser840Asn substitution encoded by exon 18 in the c-kit kinase domain. Family history suggests this exchange does not affect receptor function or cause disease. Imatinib therapy was well tolerated, stopped symptoms and disease progression, and appeared to shorten the course of the disease. Imatinib could possibly represent a novel therapeutic option in patients with progressive CM.
Find related publications in this database (using NLM MeSH Indexing)
Amino Acid Substitution -
Antineoplastic Agents - therapeutic use
Child, Preschool -
Germ-Line Mutation -
Humans -
Infant -
Male -
Mastocytosis, Cutaneous - drug therapy Mastocytosis, Cutaneous - enzymology Mastocytosis, Cutaneous - genetics Mastocytosis, Cutaneous - pathology
Piperazines - therapeutic use
Proto-Oncogene Proteins c-kit - genetics
Pyrimidines - therapeutic use
Sequence Deletion -

© Med Uni Graz Impressum